VivoSeq
Oncology

Bladder Cancer

319

Pipeline Programs↗

174

Active Trials↗

114

Companies Involved↗

Bladder Cancer is a highly competitive landscape with 319 programs across 114 companies. The most active players are Astellas, Halozyme Therapeutics, BeiGene. 8 therapies are approved with 74 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

90/100

Pipeline Velocity

63/100

Mech. Concentration

7/100

Completion Rate

71/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

1 program

Phase 1H

Halozyme Therapeutics

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 1B

BioNTech US Inc.

1 program

Phase 1R

Rondo Therapeutics

1 program

Phase 1A

Aura Biosciences

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical22

Nivolumab

Bristol-Myers Squibb

Atezolizumab

Roche

Sacituzumab

Gilead

Pioglitazone

Takeda

Standard Chemotherapy

Roche

Phase 174

Sirolimus

Prism Pharmaceuticals

Cyclophosphamide

Baxter Healthcare Corporation

Daratumumab

Johnson & Johnson

Tislelizumab

BeiGene

Avelumab

EMD Serono

Phase 2141

Erdafitinib

Johnson & Johnson

Trastuzumab

Organon and Co

Pemigatinib

Incyte

Olaparib

AstraZeneca

Futibatinib

Taiho Oncology, Inc.

Phase 374

Pembrolizumab

Merck & Co.

Enfortumab Vedotin

Pfizer

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Bacillus Calmette-Guerin

AstraZeneca

Carboplatin

Avyxa

Approved8

Propofol

Fresenius Kabi Oncology Ltd.

Rocuronium

Fresenius Kabi Oncology Ltd.

Remimazolam

Acacia Pharma Ltd

Metformin Hydrochloride

Boehringer Ingelheim

Tamsulosin

Sanofi

Analysis

Modality Breakdown

81%

Small molecule

261 of 324 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody3812%Vaccine82%Antibody–drug conjugate72%Protein / enzyme52%Gene therapy41%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 324 classified programs, each share of the total. Modality classified for 98% of 379 pipeline programs.

Analysis

Trial Status

518

clinical trials

Completed195 · 38%
Recruiting79 · 15%
Unknown status64 · 12%
Active, not recruiting61 · 12%
Terminated53 · 10%
Not yet recruiting33 · 6%
Other33 · 6%

Clinical Trials

Trial Activity

518 trials

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Recruiting·FFujian Medical University Union Hospital·Phase 3·NCT06441110·76 enrolled
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Recruiting·UUniversity Hospital, Ghent·Phase 2·NCT04724928·156 enrolled
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Recruiting·EEmory University·Phase 2·NCT05756569·25 enrolled
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Recruiting·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 1·NCT06108492·170 enrolled
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Recruiting·RRemeGen Co., Ltd.·Phase 1/2·NCT06378242·24 enrolled
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Recruiting·AAura Biosciences·Phase 1·NCT05483868·55 enrolled
The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer
Recruiting·—·Phase 4·NCT06215976·78 enrolled
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Recruiting·UUniversity of California, Davis·Phase 1·NCT05843448·30 enrolled
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
Recruiting·PPeking University First Hospital·Phase 2·NCT05072600·54 enrolled
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Recruiting·—·Phase 2·NCT06263153·24 enrolled
Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia
Recruiting·UUniversity of Erlangen-Nürnberg Medical School·N/A·NCT05397262·1,000 enrolled
Chemoablation for Low-Grade Bladder Cancer
Recruiting·—·Phase 2·NCT07019220·47 enrolled
Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1·NCT06551233·30 enrolled
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05239624·23 enrolled
Radiation Therapy in Unresectable Gall Bladder Cancer
Recruiting·TTata Memorial Centre·Phase 2/3·NCT06214572·249 enrolled
Page 1 of 35

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)